SCHEMBL3021636

SCHEMBL3021636

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 2/20 0.37
CTSS P25774 5/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR6 P50406 1/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
ADRB2 P07550 1/20 0.36
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KDM4E B2RXH2 1/20 0.35
F2 P00734 1/20 0.35
F2RL3 Q96RI0 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017937 0.93 TP53 (0.39) SMN1; SMN2RAB9AALDH1A1HPGDHSD17B10
SCHEMBL3013303 0.93 MAPT (0.37) SMN1; SMN2RAB9ACTSSALDH1A1HPGD
SCHEMBL3002108 0.93 ALDH1A1 (0.39) SMN1; SMN2RAB9AALDH1A1HPGDHSD17B10
SCHEMBL3001183 0.93 RAB9A (0.35) SMN1; SMN2RAB9ACTSSALDH1A1HPGD
SCHEMBL3006774 0.93 CTSS (0.42) SMN1; SMN2RAB9ACTSSALDH1A1HPGD
SCHEMBL3003638 0.92 CTSS (0.40) SMN1; SMN2RAB9ACTSSALDH1A1HPGD
SCHEMBL3019361 0.91 RAB9A (0.39) SMN1; SMN2RAB9AALDH1A1HPGDHSD17B10
SCHEMBL3014455 0.90 ALDH1A1 (0.37) SMN1; SMN2RAB9AALDH1A1HPGDHSD17B10
SCHEMBL3017810 0.90 ALDH1A1 (0.40) SMN1; SMN2RAB9AALDH1A1HPGDHSD17B10
SCHEMBL3015201 0.90 MAPT (0.37) SMN1; SMN2RAB9AALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885CTSS 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.